Transfection innovation for large scale AAV and LV – Considerations for process development through commercial manufacturing

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Transfection innovation for large scale AAV and LV – Considerations for process development through commercial manufacturing

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

GMP-compliant nucleic acid delivery to HEK 293 cells is often a critical first step in the manufacture of advanced therapies utilizing recombinant adeno-associated virus (AAV) or lentivirus (LV) to facilitate delivery of a therapeutic transgene to patients. Accordingly, the need for safe and reproducible large-scale viral vector manufacture processes has never been greater. Mirus Bio has developed a fully synthetic, innovative transfection formulation to enable higher titer AAV and LV generation and reduce the cost of therapeutic development and manufacture to bring more life-changing doses to patients sooner.

Optimization strategies for achieving higher AAV and LV titers via transient transfection workflows in both adherent and suspension HEK 293 cells.
Key considerations for reagent selection and process development for a seamless transition from R&D scale to commercial manufacturing.
How VirusGEN^® GMP AAV and LV products enable significantly higher functional titers than PEI-derived polymers or liposomes alone.

Geddy Hamblen

Field Application Scientist at Mirus Bio

Geddy Hamblen is an Applications Scientist at Mirus Bio LLC, a biotech company providing innovative transfection products to cell culture researchers worldwide. Geddy has over 10 years of molecular biology and bioprocessing experience, from bench scale cloning, to pilot scale plasmid production and commercial biotherapeutic manufacturing. Geddy has a Masters degree in Biotechnology from Texas A&M University, with key interests in vector design, process development, and process characterization.